{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-000893","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.870905+00:00","generated_at":"2026-05-16T10:59:56.193199+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ionis reports TRYNGOLZA 2025 preliminary U.S. net sales of $105M, ups peak olezarsen guidance to >$2B","bullets":["TRYNGOLZA generated $105M in preliminary 2025 U.S. net product sales, outperforming expectations as first FDA-approved FCS treatment.","Annual peak net sales guidance for olezarsen in sHTG increased to >$2B from >$1B following strong Phase 3 data.","Submitted sNDA for olezarsen in severe hypertriglyceridemia; potential approval and launch anticipated in 2026.","Expects 2026 launches of zilganersen for Alexander disease (NDA in Q1) and bepirovirsen for chronic hepatitis B (with GSK).","Five Phase 3 readouts from partnered programs planned in 2026, including pelacarsen (Novartis) and eplontersen (AstraZeneca)."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-000893","json":"https://secwatch.observer/filing/0001140361-26-000893.json","markdown":"https://secwatch.observer/filing/0001140361-26-000893.md","text":"https://secwatch.observer/filing/0001140361-26-000893.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000114036126000893/0001140361-26-000893-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000114036126000893/ef20062670_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:59:56.193199+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}